This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): MF59-adjuvanted influenza vaccine, Gripguard [France], Chiromas [Spain]
Description: The adjuvanted egg-based seasonal influenza vaccine FLUAD is composed of subunit influenza antigens combined with the MF59-adjuvant emulsion. M59 is a water suspension adjuvant based on squalene.
Deal Structure: In 2000, Chiron entered into a co-promotion and co-marketing agreement with Aventis Pasteur MSD related to Fluad.
Novartis completed its acquisition of Chiron (including its vaccines) in April 2006.
Novartis and CSL
In October 2014, Novartis entered into a definitive agreement to divest its influenza vaccines business to CSL Limited (CSL) for an agreed price of USD 275 million. This transaction requires regulatory approvals and is expected to close in the second half of 2015.
In August 2015, CSL announced that it has closed ts transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million.
Sequirus and Valneva
In August 2016, Valneva announced the signing of an agreement with Seqirus for the marketing & distribution of Seqirus seasonal flu vaccines Sandovac and Fluad in the Austrian market.
Partners: Valneva SE
Additional information available to subscribers only: